(0.22%) 5 117.75 points
(0.01%) 38 731 points
(0.67%) 17 725 points
(-0.04%) $83.33
(-0.17%) $1.809
(-0.35%) $2 334.00
(-0.21%) $27.31
(0.49%) $927.30
(0.13%) $0.935
(0.22%) $10.93
(0.16%) $0.804
(-0.63%) $92.60
-92.64% $ 0.00850
Live Chart Being Loaded With Signals
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties...
Stats | |
---|---|
Today's Volume | 1.94M |
Average Volume | 876 957 |
Market Cap | 582 482 |
EPS | $0 ( 2023-11-08 ) |
Last Dividend | $0.110 ( 2023-04-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.142 |
ATR14 | $0.00500 (58.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-15 | Hogan H Michael Iii | Buy | 0 | |
2022-12-30 | Weber David Allen | Sell | 91 636 | Common Stock |
2022-12-28 | Cayer Paul E | Sell | 40 054 | Common Stock |
2022-11-28 | Capps Vickie L | Sell | 42 242 | Common Stock |
2022-06-21 | Schroeder Theodore R | Buy | 27 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
-32.14 |
Last 98 transactions |
Buy: 7 968 332 | Sell: 3 029 863 |
Volume Correlation
Otonomy Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Otonomy Inc Correlation - Currency/Commodity
Otonomy Inc Financials
Annual | 2021 |
Revenue: | $125 000 |
Gross Profit: | $-245 000 (-196.00 %) |
EPS: | $-0.810 |
Q3 | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.180 |
Q2 | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.200 |
Q1 | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.210 |
Financial Reports:
No articles found.
Otonomy Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.110 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.110 | 2023-04-11 |
Last Dividend | $0.110 | 2023-04-11 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.110 | -- |
Avg. Dividend % Per Year | 39.17% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.110 | 117.50% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -402.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.526 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0949 | 1.500 | -0.0565 | -0.0848 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.52 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.166 | -1.500 | 7.24 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -31.04 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.337 | -0.673 | [0 - 20] |
debtEquityRatioTTM | -0.0285 | -1.500 | -0.114 | 0.171 | [0 - 2.5] |
grossProfitMarginTTM | -1.960 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -397.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.68 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00131 | 0.800 | -3.32 | -2.66 | [0.5 - 2] |
Total Score | -3.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0107 | 1.000 | -0.102 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0949 | 2.50 | -0.0363 | -0.0848 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.224 | -0.673 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -339.34 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.609 |
Otonomy Inc
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators